AI Article Synopsis
- Cardiac transplants for amyloidosis used to be seen as too risky because of high complications and death rates.
- Advances in treatments for AL and ATTR amyloidosis and better screening have significantly improved transplant success in the last decade or so.
- There are few mechanical support options for patients, but they could be beneficial for certain individuals, especially those with larger heart chambers, highlighting a need to rethink how we prioritize heart transplants for amyloidosis patients, especially those with AL.
Article Abstract
• Cardiac transplantation for amyloidosis was once considered contraindicated owing to unacceptably high morbidity/mortality rates. • Increased therapeutic options for AL and ATTR amyloidosis and improved pre-transplantation screening practices have led to markedly improved transplant outcomes over the past 10-15 years. • Mechanical circulatory support options remain limited but can be considered in selected patients, particularly for those with larger ventricular cavities. • Transplant prioritization rules may need to be reconsidered for amyloidosis patients to adequately prioritize AL amyloidosis patients, who are at increased risk of pre-transplantation mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543081 | PMC |
| http://dx.doi.org/10.1016/j.jaccao.2021.05.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!